Study of ISM6331 for advanced mesothelioma or other solid tumors
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new drug called ISM6331 for people with advanced mesothelioma or other solid tumors that have not responded to standard treatments. The drug targets a specific pathway that may help stop tumor growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You have mesothelioma or another solid tumor that has spread or cannot be removed by surgery.
- You have tried standard treatments (like chemotherapy for mesothelioma) and they did not work, or no standard treatment exists.
- For non-mesothelioma tumors, a genetic test must show changes in the Hippo pathway.
- You are well enough to be up and about (ECOG score 0 or 1).
- You have at least one tumor that can be measured on a scan.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new oral drug called ISM5939 for people with advanced or metastatic solid tumors. It aims to see if the drug is safe and helps shrink or control cancer when other treatments have stopped working.
This clinical trial tests an experimental drug called HY05350 for people with advanced solid tumors that have a specific protein (mesothelin). It aims to see if the drug is safe and effective for cancers that have not responded to standard treatments.
This early study tests a new medicine (BPI-460372) in adults with advanced solid cancers that have come back or can’t be treated with standard options. It may help by targeting specific cancer changes in certain tumors, and doctors will also learn the safest dose.
This trial tests a new drug called LPM6690176 for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if it is safe and how it affects the body.
This early-phase study tests STI-7349 (a new cancer treatment) in people with advanced solid tumors that have not responded to standard treatments. The goal is to find a safe dose and see how well it can control cancer.
This study tests a new oral drug called ISM3412 for people with advanced solid tumors that have a specific genetic change (MTAP deletion). The goal is to see if the drug can shrink tumors or slow their growth.
Hear when a new Advanced Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.